Table 1:
Sample characteristics overall and stratified by ePVS burden
| Centrum Semiovale (CSO) | Basal Ganglia (BG) | CSO-BG Mixed Scorea | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall N=3,564 | Grade I-II N=2,933 | Grade III-IV N=630 | Grade I-II N=3,216 | Grade III-IV N=348 | None N=2,809 | One N=530 | Both N=224 | |
| Clinical Characteristics | ||||||||
| Male, n (%) | 1644 (43) | 1376 (47) | 267 (42) | 1497 (47) | 147 (42) | 1322 (47) | 228 (43) | 93 (42) |
| Age at exam closest to baseline MRI, yrs, mean [SD] | 59.1 (14.8) | 55.8 (14) | 72.2 (10.9) | 56.9 (14.2) | 75.4 (9.8) | 55.1 (13.6) | 70.7 (10.8) | 76.5 (9.5) |
| Age at MRI, yrs, mean [SD] | 61.1 (14.5) | 57.9 (13.8) | 73.9 (10.6) | 59.0 (14) | 77.1 (9.4) | 57.1 (13.4) | 72.4 (10.5) | 78.2 (9.1) |
| APOE ε4+, n (%) | 836 (23) | 663 (23) | 173 (27) | 752 (23) | 84 (24) | 639 (23) | 137 (26) | 60 (27) |
| APOE genotypes, n (%) | ||||||||
| ε2/ε2 | 19 (1) | 17 (1) | 2 (0) | 18 (1) | 1 (0) | 17 (1) | 1 (0) | 1 (0) |
| ε2/ε3 | 442 (12) | 383 (13) | 79 (12) | 415 (12) | 47 (13) | 363 (12) | 72 (13) | 27 (11) |
| ε2/ε4 | 75 (2) | 57 (2) | 20 (3) | 74 (2) | 3 (1) | 55 (2) | 21 (4) | 1 (0) |
| ε3/ε3 | 2267 (64) | 1968 (64) | 413 (61) | 2148 (64) | 233 (63) | 1880 (64) | 356 (62) | 145 (62) |
| ε3/ε4 | 699 (20) | 583 (19) | 146 (22) | 654 (19) | 75 (20) | 562 (19) | 113 (20) | 54 (23) |
| ε4/ε4 | 62 (2) | 48 (2) | 14 (2) | 54 (2) | 8 (2) | 47 (2) | 8 (1) | 7 (3) |
| FHS cohort, n (%) | ||||||||
| Original | 177 (5) | 72 (2) | 105 (17) | 108 (3) | 69 (20) | 59 (2) | 62 (12) | 56 (25) |
| Offspring | 1482 (42) | 1049 (36) | 432 (69) | 1243 (39) | 239 (69) | 958 (34) | 375 (71) | 148 (66) |
| NOS/Third Gen | 1775 (50) | 1700 (58) | 75 (12) | 1748 (54) | 27 (8) | 1690 (60) | 68 (13) | 17 (8) |
| OMNI 1 | 130 (4) | 112 (4) | 18 (3) | 117 (4) | 13 (4) | 102 (4) | 25 (5) | 3 (1) |
| Time between exam and MRI, yrs, mean (SD) | 2.0 (1.1) | 2.1 (1.0) | 1.7 (1.1) | 2.0 (1.1) | 1.6 (1.1) | 2.1 (1.0) | 1.7 (1.1) | 1.6 (1.2) |
| Vascular risk factors | ||||||||
| Systolic blood pressure, mm Hg, mean [SD] | 123.0 (17.3) | 120.9 (16.3) | 131.2 (18.8) | 121.4 (16.5) | 135.2 (18.9) | 120.4 (16.0) | 129.6 (18.8) | 136.2 (18.5) |
| Diastolic blood pressure, mm Hg, mean [SD] | 73.1 (9.8) | 73.5 (9.6) | 71.1 (10.3) | 73.2 (9.6) | 73 (9.9) | 73.6 (9.5) | 71.4 (10.3) | 70.9 (10.7) |
| Hypertensionb, n (%) | 1486 (42) | 1063 (36) | 423 (67) | 1223 (38) | 263 (76) | 975 (35) | 336 (64) | 175 (78) |
| Current smokers, n (%) | 272 (8) | 226 (8) | 46 (7) | 256 (8) | 16 (5) | 221 (8) | 40 (8) | 11 (5) |
| Diabetes mellitus, n (%) | 372 (11) | 272 (9) | 100 (17) | 324 (10) | 48 (15) | 254 (9) | 88 (18) | 30 (15) |
| Antihypertensive use, n (%) | 1219 (34) | 867 (30) | 352 (57) | 994 (31) | 225 (65) | 789 (28) | 283 (54) | 147 (66) |
| Cerebral Microbleeds | ||||||||
| Any CMB N=2,046 | 100 (5) | 78 (4) | 22 (10) | 85 (4) | 15 (17) | 76 (4) | 11 (7) | 13 (20) |
| Any Lobar N=2,032 | 86 (4) | 68 (4) | 18 (9) | 73 (4) | 13 (15) | 66 (4) | 9 (6) | 11 (17) |
| Any Deep N=1971 | 25 (1) | 15 (1) | 10 (5) | 20 (1) | 5 (6) | 15 (1) | 5 (3) | 5 (9) |
| Deep and Lobar N=1957 | 11 (1) | 5 (0) | 6 (3) | 8 (0) | 3 (4) | 5 (0) | 3 (2) | 3 (5) |
| Deep or Mixed N=1971 | 25 (1) | 15 (1) | 10 (5) | 20 (1) | 5 (6) | 15 (1) | 5 (3) | 5 (9) |
a
Number of CSO-BG regions with high ePVS burden (0=none, 1=one region, or 2=both regions); high burden is defined as grade III or IV ePVS
b
Hypertension is defined as SBP ≥140 mmHg or DBP ≥90 mmHg and/or use of antihypertensive medication